RAN-MINOCYCLINE CAPSULE

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

MINOCYCLINE (MINOCYCLINE HYDROCHLORIDE)

から入手可能:

RANBAXY PHARMACEUTICALS CANADA INC.

ATCコード:

J01AA08

INN（国際名）:

MINOCYCLINE

投薬量:

100MG

医薬品形態:

CAPSULE

構図:

MINOCYCLINE (MINOCYCLINE HYDROCHLORIDE) 100MG

投与経路:

ORAL

パッケージ内のユニット:

10/500

処方タイプ:

Prescription

治療領域:

TETRACYCLINES

製品概要:

Active ingredient group (AIG) number: 0131309002; AHFS:

認証ステータス:

APPROVED

承認日:

2012-07-27

製品の特徴

_RAN-MINOCYCLINE (minocycline hydrochloride) Product Monograph Page 1
of 35_
PRESCRIBING INFORMATION
PR
RAN™-MINOCYCLINE
(MINOCYCLINE HYDROCHLORIDE)
CAPSULES 50 MG AND 100 MG MINOCYCLINE (AS MINOCYCLINE HYDROCHLORIDE)
USP
ANTIBIOTIC
Ranbaxy Pharmaceuticals Canada Inc.
126 East Drive
Brampton, Ontario
L6T 1C1
Date of Revision:
November 7, 2018
Submission Control Number: 220690
_ _
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
_ _
_ _
_ _
_ _
_RAN-MINOCYCLINE (minocycline hydrochloride) Product Monograph Page 2
of 35_
COMPLETE PRESCRIBING INFORMATION
Pr
RAN™-MINOCYCLINE
(minocycline hydrochloride)
THERAPEUTIC CLASSIFICATION
Antibiotic
ACTIONS
Minocycline hydrochloride is a tetracycline with antibacterial
activity against some Gram-negative
and Gram-positive organisms. The action of RAN-MINOCYCLINE is
primarily bacteriostatic and
is thought to exert its antimicrobial effect by the inhibition of
protein synthesis.
INDICATION AND CLINICAL USES
RAN-MINOCYCLINE
(minocycline hydrochloride) may be indicated for the treatment of the
following infections due to susceptible strains of the designated
organisms:
Gall bladder infections caused by
_Escherichia coli_
.
Urinary tract infections: cystitis, gonorrhea, pyelonephritis caused
by
_Escherichia coli_
,
_Proteus _
_species,_
_Klebsiella _
species,
_Enterobacter aerogenes_
,
_Neisseria gonorrhea. _
When penicillin is contraindicated, minocycline may be employed as an
alternative drug in the
treatment of anal and pharyngeal gonorrhea and syphilis.
Skin and soft tissue infections: abscess, cellulitis, furunculosis,
impetigo and pyoderma caused by:
_Staphylococcus epidermidis. Staphylococcus aureus, Streptococcus
pyogenes, Proteus species,_
_Escherichia coli_
. Although tetracyclines are not the drugs of choice in any
staphylococcal or
streptococcal infection minocycline could be useful in circumstances
where these organisms are
shown to be resistant to other agents but sensitive to minocycline.
Bacterial evaluation of clinical
cases involving proteus suggests